about
Clonal evolution models of tumor heterogeneityEvidence for the initiation of decompression sickness by exposure to intense underwater sound.Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310FRisk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy.Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in LAT.RIN2 deficiency results in macrocephaly, alopecia, cutis laxa, and scoliosis: MACS syndromeMacrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3Theranostic barcoded nanoparticles for personalized cancer medicineWhat are melanocytes really doing all day long...?The antiangiogenic role of the pro-inflammatory cytokine interleukin-31.KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature.LNA-based PCR clamping enrichment assay for the identification of KRAS mutations.Post-irradiation angiosarcoma of the breast: clinical presentation and outcome in a series of six cases.Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea.Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.Comparative incidence of acute Q fever in two ethnic groups in Israel.Correction: Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in LAT.Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel.Normal colon tissue and colon carcinoma show no difference in heparanase promoter methylation.Defective lamellar granule secretion in arthrogryposis, renal dysfunction, and cholestasis syndrome caused by a mutation in VPS33B.Synthetic Cells Synthesize Therapeutic Proteins inside Tumors.Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.Nanoparticles target early-stage breast cancer metastasis in vivo.Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.Proteolytic Nanoparticles Replace a Surgical Blade by Controllably Remodeling the Oral Connective Tissue.A deep penetrating facial congenital melanocytic tumor with bone involvement and ipsilateral eye blindness.Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.Hairy cell leukemia-variant without typical morphology and with near-tetraploid DNA content.Vestibular evoked myogenic potentials and motion sickness medications.Subclonality for BRAF Mutation in Papillary Thyroid Carcinoma Is Associated With Earlier Disease Stage.Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer.Novel mutations in DSG1 causing striate palmoplantar keratoderma.RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations.Familial cutaneous collagenomas resulting from a novel mutation in LEMD3Appropriateness of antibiotic therapy on weekends versus weekdays
P50
Q26863470-78E1DACB-2759-46F9-8593-989D181EF2A1Q30375356-352BD21A-E5F7-4DFF-8D6F-C3401B39F431Q33628057-CF1CA401-CD17-4FF7-A07A-5157C81D369AQ34127918-B0C84BA0-5C1A-4386-B1F5-13E71ECED643Q36306292-F872B4FF-4628-4922-AA01-0B32D97472BDQ37047281-49B07886-3AEB-4DE9-8A69-ED449AA8EFBEQ37301164-981940BF-B720-4641-9408-683B337362C0Q37397162-F9B5AD75-F52D-4E64-9E32-3577F9E056F4Q37414318-4FE1019D-1BE4-49BE-AEFA-01C381BAD3F3Q37472801-6CABA8DC-0D2F-4C70-9A53-2648D52CA7D0Q37725449-00D87393-F589-4744-ADB1-56DF3A42ED2AQ38178343-F1E5025A-D48A-46A2-8805-D2D9B792E34BQ38418494-2CB9D2F3-8BDA-43C3-AA11-FB96E0E4A48CQ38553228-3276F8DD-CF42-4C14-AC3A-41DD2E720820Q38571253-6F9219EC-7396-4203-9EC8-986EC946F38CQ38594037-EBBAE81D-F5F5-4FD3-8D55-BF9C4678B50CQ40539525-588883BA-6276-4C21-92D7-7F44FF95DFD6Q40964678-6D86FA03-9316-4CC9-A052-9A05256421C4Q41233667-D5E6818A-C959-41FF-92C1-63AD1249C1E1Q41996754-C9A1E05E-7AF3-4EA5-85BD-0E5310B9320EQ44985584-852FC3A4-5C7B-4460-9D2C-95EAA87B6F68Q45330266-A29D557C-EF05-49BA-87E8-0267FBE00081Q47214708-4F70C80B-AC0F-4C23-9145-EEB8C45895ABQ47401147-56D48941-AF2A-4743-96C0-3005C4FBA307Q47548311-E586EC25-188F-4117-9C9A-3C54B76A79BBQ47716951-BB7E0416-9B50-4587-A425-F1227FCB6434Q48163413-A93291A6-E8EA-4090-859E-7813985DD82AQ48173639-CFA78A29-1B96-4BAB-A040-882879E5CFA4Q50222155-D2F04BDB-853B-4EC1-BAC9-E60B321E243AQ50708918-D168FCFD-27ED-430F-B1CE-B2006F4434A2Q52147073-E53FA62A-E060-4DB6-BCC1-5D5FAA0F1192Q52939133-6E17FBC8-A96B-4975-B501-6B46A3171FD8Q53099627-DB73DF98-AE2C-4FD3-9266-BA4AC7A9B5D4Q53187389-2F69C383-4683-4923-BBF6-25D096D62D59Q53209735-880AC242-8818-44A6-AAFE-9D9102285A50Q54342995-63AF50D5-8BBF-4606-AC5A-99D8242C8823Q54506985-D2E26A10-E7E8-4645-B7BE-832E8B4850B5Q54540655-D3DE8F2D-2791-4839-BA9C-5C8C582BBD52Q79560577-48458AD3-4A28-4B91-8488-954480413FD3Q80535585-41325612-C8DB-42DD-8280-CD9841EC8D84
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dov Hershkovitz
@en
Dov Hershkovitz
@es
Dov Hershkovitz
@nl
Dov Hershkovitz
@sl
type
label
Dov Hershkovitz
@en
Dov Hershkovitz
@es
Dov Hershkovitz
@nl
Dov Hershkovitz
@sl
prefLabel
Dov Hershkovitz
@en
Dov Hershkovitz
@es
Dov Hershkovitz
@nl
Dov Hershkovitz
@sl
P106
P1153
6506556996
P31
P496
0000-0002-7954-4486